Table 2 Effects of age and common prognostic factors on overall survival in multiple imputed data sets.
From: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Predictor | Univariable models | Multivariable models | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | |
Full sample set of patients with HCC (n = 5598) | ||||
Age ≥75 years | 1.00 (0.93–1.08) | 0.9 | 1.03 (0.95–1.12) | 0.5 |
BCLC stage C or D vs 0, A or B | 2.04 (1.88–2.22) | <0.001 | 1.57 (1.43–1.73) | <0.001 |
CTP class (B, C vs A) | 2.28 (2.13–2.44) | <0.001 | 2.15 (2.01–2.30) | <0.001 |
Tumour size >7 cm | 1.80 (1.63–1.98) | <0.001 | 1.57 (1.43–1.73) | <0.001 |
PVT | 1.05 (0.98–1.12) | 0.1 | 1.02 (0.96–1.09) | 0.5 |
Presence of metastasis | 1.50 (1.37–1.64) | <0.001 | 1.20 (1.08–1.32) | <0.001 |
AFP > 400 ng/dL | 1.88 (1.74–2.04) | <0.001 | 1.70 (1.57–1.85) | <0.001 |
HCV vs other aetiologies | 0.86 (0.82–0.91) | <0.001 | 0.88 (0.83–0.94) | <0.001 |
Starting dose (800 mg vs 200/400 mg) | 0.94 (0.89–1.00) | 0.05 | 0.96 (0.91–1.02) | 0.29 |
Continent (Asia vs USA/Europe) | 0.74 (0.64–0.85) | <0.001 | 0.78 (0.67–0.89) | <0.001 |
Patients aged >75 years with HCC (n = 792) | ||||
BCLC stage C or D vs 0, A or B | 1.50 (1.28–1.76) | <0.001 | 1.19 (0.98–1.45) | 0.08 |
CTP class (B, C vs A) | 2.35 (1.91–2.89) | <0.001 | 2.23 (1.81–2.76) | <0.001 |
Tumour size >7 cm | 1.56 (1.30–1.87) | <0.001 | 1.37 (1.13–1.65) | <0.01 |
PVT | 1.20 (1.00–1.44) | 0.05 | 1.08 (0.90–1.30) | 0.4 |
Presence of metastasis | 1.39 (1.16–1.65) | <0.01 | 1.13 (0.91–1.39) | 0.3 |
AFP > 400 ng/dL | 1.70 (1.37–2.10) | <0.001 | 1.56 (1.26–1.95) | <0.001 |
HCV vs other aetiologies | 0.65 (0.54–0.79) | <0.001 | 0.70 (0.58–0.86) | <0.001 |
Starting dose (800 mg vs 200/400 mg) | 1.07 (0.92–1.25) | 0.3823 | 0.95 (0.82–1.12) | 0.5671 |
Continent (Asia vs USA/Europe) | 0.60 (0.45–0.79) | <0.001 | 0.80 (0.60–1.07) | 0.1334 |
